Meeting
2019 ASCO Annual Meeting
Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
Authors
Jamie E. Chaft
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Jamie E. Chaft , Daniel Botelho Costa , Alona Muzikansky , Joseph B Shrager , Michael Lanuti , James Huang , Kavitha Ramchandran , Deepa Rangachari , Mark Huberman , Zofia Piotrowska , Mark G. Kris , Christopher G. Azzoli , Lecia V. Sequist , Joel W. Neal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01746251
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8507)
DOI
10.1200/JCO.2019.37.15_suppl.8507
Abstract #
8507
Poster Bd #
263
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2019 ASCO Annual Meeting
Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.
First Author: Alexandra Pender
Poster
2018 ASCO Annual Meeting
A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.
First Author: Kazuhiko Yamada
Poster
2017 ASCO Annual Meeting
Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study).
First Author: Akito Hata